ONO-8130
CAS No. 459841-96-4
ONO-8130( —— )
Catalog No. M24411 CAS No. 459841-96-4
ONO-8130 is an orally available antagonist of EP1 receptor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 457 | In Stock |
|
| 5MG | 342 | In Stock |
|
| 10MG | 563 | In Stock |
|
| 25MG | 901 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameONO-8130
-
NoteResearch use only, not for human use.
-
Brief DescriptionONO-8130 is an orally available antagonist of EP1 receptor.
-
DescriptionONO-8130 is an orally available antagonist of EP1 receptor.
-
In Vitro——
-
In VivoONO-8130 (0.3-30 mg/kg; Oral preadministration, once) strongly prevents both the bladder pain-like behavior and referred hyperalgesia in a dose-dependent manner.ONO-8130 (30 mg/kg; Orally, once) reverses the established cystitis-related bladder pain.ONO-8130 (30 mg/kg; Orally, once) strongly inhibits phosphorylation of ERK in MDH, DCM, and SPN of the L6 spinal cord caused by intravesical administration of PGE2. Animal Model:Female ddY mice (18-22 g, 4-5 weeks old)Dosage:0.3, 3, 10, and 30 mg/kg Administration: Orally, once Result:Strongly prevented both the bladder pain-like behavior and referred hyperalgesia in a dose-dependent manner, but had slight effect on the increased bladder weight and vascular permeability.Animal Model:Female ddY mice (18-22 g, 4-5 weeks old, established bladder pain caused by IP cyclophosphamide)Dosage:10, 30 mg/kgAdministration:Orally, once (administered 2.75 hours after i.p. cyclophosphamide) Result:Markedly attenuated the bladder pain-like nociceptive behavior and referred hyperalgesia in the acute phase (3.5-4 h after cyclophosphamide).Animal Model:Female ddY mice (18-22 g, 4-5 weeks old, established bladder pain caused by IP cyclophosphamide)Dosage:30 mg/kgAdministration:Orally, once (administered 4.75 hours after i.p. cyclophosphamide)Result:Significantly suppressed the bladder pain-like nociceptive behavior and tended to reduce the referred hyperalgesia in the persistent phase, 5.5-6 hours after cyclophosphamide.Animal Model:Female ddY mice (18-22 g, 4-5 weeks old, intravesical administration of PGE2 at 5 nmol/mouse)Dosage:30 mg/kg Administration:Orally, once Result:Strongly inhibited phosphorylation of ERK in MDH, DCM, and SPN of the L6 spinal cord caused by intravesical administration of PGE2 at 5 nmol/mouse, exerted complete blockade in DCM, while its inhibitory effects in MDH and SPN were partial.
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetProstaglandin Receptor
-
RecptorEP1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number459841-96-4
-
Formula Weight500.63
-
Molecular FormulaC25H28N2O5S2
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESCC1=CSC(=N1)S(=O)(=O)N(CC(C)C)C2=C(C=C3CCCC3=C2)OCC4=CC=C(C=C4)C(=O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Treprostinil diethan...
Treprostinil diethanolamine (UT-15C) is a potent agonist of EP2, DP1, and IP, with values of 3.6, 4.4, and 32.1 nM for EP2, DP1, and IP, respectively, and 212, 826, 2505, and 4680 nM for EP1, EP4, EP3, and FPKi, respectively.
-
GW 627368X
GW627368(GW627368X) is a novel, potent and selective competitive antagonist of prostanoid EP4 receptor(Ki= 100 nM) with additional human TP receptor affinity(Ki= 150 nM).
-
Saikogenin D
Saikogenin D is isolated from?Bupleurum chinense, has anti-inflammatory effects. Saikogenin D activates epoxygenases that converts arachidonic acid to epoxyeicosanoids and dihydroxyeicosatrienoic acids, and the metabolites secondarily inhibit prostaglandin E2 (PGE2) production. Saikogenin D results in an elevation of [Ca2+]i due to Ca2+ release from intracellular stores.
Cart
sales@molnova.com